BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 19531930)

  • 1. CMV DNA levels and CMV gB subtypes in ART-naive HAART-treated patients: a 2-year follow-up study in The Netherlands.
    Goossens VJ; Wolffs PF; van Loo IH; Bruggeman CA; Verbon A
    AIDS; 2009 Jul; 23(11):1425-9. PubMed ID: 19531930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Genotyping of viral glycoprotein B (gB) in hematopoietic stem cell transplant recipients with active cytomegalovirus infection: analysis of the impact of gB genotypes on the patients' outcome].
    Roubalová K; Strunecký O; Zufanová S; Procházka B; Vitek A
    Epidemiol Mikrobiol Imunol; 2010 Apr; 59(2):92-9. PubMed ID: 20586171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy.
    Gourlain K; Salmon D; Gault E; Leport C; Katlama C; Matheron S; Costagliola D; Mazeron MC; Fillet AM; ;
    J Med Virol; 2003 Mar; 69(3):401-7. PubMed ID: 12526052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy.
    Song MK; Karavellas MP; MacDonald JC; Plummer DJ; Freeman WR
    Retina; 2000; 20(2):151-5. PubMed ID: 10783947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of highly active antiretroviral therapy on cytomegalovirus viraemia in the absence of specific anti-cytomegalovirus therapy.
    Mihăilescu R; Arama V; Paraschiv S; Streinu-Cercel A; Oţelea D; Munteanu D; Iosipenco M; Chiotan C; Benea OE; Mărdărescu M; Rădulescu M; Hristea A; Ungurianu R; Aramă SS; Cercel AS; Călin R; Băicuş C
    Rom J Intern Med; 2008; 46(4):305-11. PubMed ID: 19480296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
    Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Incidence and evaluation of viral retinitis in patients infected with the HIV virus and treated with HIV protease inhibitors].
    Labetoulle M; Goujard C; Frau E; Rogier H; Niessen F; Rudent A; Lantz O; Lecointe D; Furlan V; Delfraissy JF; Offret H
    J Fr Ophtalmol; 1998 Oct; 21(8):567-76. PubMed ID: 9833222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease.
    Manuel O; Asberg A; Pang X; Rollag H; Emery VC; Preiksaitis JK; Kumar D; Pescovitz MD; Bignamini AA; Hartmann A; Jardine AG; Humar A
    Clin Infect Dis; 2009 Oct; 49(8):1160-6. PubMed ID: 19751151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naïve and HAART-treated individuals.
    Gibellini D; Borderi M; De Crignis E; Cicola R; Cimatti L; Vitone F; Chiodo F; Re MC
    J Infect; 2008 Mar; 56(3):219-25. PubMed ID: 18276011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
    Masciotra S; Garrido C; Youngpairoj AS; McNulty A; Zahonero N; Corral A; Heneine W; de Mendoza C; García-Lerma JG
    AIDS; 2007 Nov; 21(18):2503-11. PubMed ID: 18025887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
    Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
    BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus glycoprotein B genotypes and central nervous system disease in AIDS patients.
    Vilas Boas LS; de Souza VA; Penalva de Oliveira AC; Rodriguez Viso AT; Nascimento Filho AM; Nascimento MC; Pannuti CS
    J Med Virol; 2003 Nov; 71(3):404-7. PubMed ID: 12966546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy.
    Bossolasco S; Calori G; Moretti F; Boschini A; Bertelli D; Mena M; Gerevini S; Bestetti A; Pedale R; Sala S; Sala S; Lazzarin A; Cinque P
    Clin Infect Dis; 2005 Mar; 40(5):738-44. PubMed ID: 15714422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction.
    Francisci D; Giannini S; Baldelli F; Leone M; Belfiori B; Guglielmini G; Malincarne L; Gresele P
    AIDS; 2009 Mar; 23(5):589-96. PubMed ID: 19177019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.
    Kolte L; Ryder LP; Albrecht-Beste E; Jensen FK; Nielsen SD
    Scand J Immunol; 2009 Dec; 70(6):608-13. PubMed ID: 19906203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.